Soleno Therapeutics Shareholder Files Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SLNO?
Source: Globenewswire
- Class Action Initiated: Bernstein Liebhard LLP announced that a shareholder has filed a class action lawsuit on behalf of investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) stock between March 26, 2025, and August 4, 2025, alleging misrepresentations regarding the company's Phase 3 clinical trial for DCCR, which may have led to investor losses.
- Lawsuit Details Revealed: The lawsuit requires interested parties to file as lead plaintiff by May 5, 2026, indicating that while the lead plaintiff will represent the class, absent members can still share in any recovery, highlighting the complexities of legal proceedings and the protection of investor rights.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, underscoring its expertise and influence in securities litigation.
- Investor Rights Protection: The initiation of this lawsuit not only provides a legal recourse for affected investors but also emphasizes the need for transparency in corporate communications, potentially prompting the company to enhance compliance and disclosure practices in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.250
Low
75.00
Averages
110.50
High
125.00
Current: 52.250
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Shareholder Notice Issued
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Soleno Therapeutics, Inc., encouraging those who purchased SLNO shares between March 26, 2025, and November 4, 2025, to contact the firm regarding potential lead plaintiff status for recovery participation.
- Safety Concerns Allegations: The complaint alleges that Soleno systematically downplayed and concealed significant safety concerns related to its DCCR product during Phase 3 clinical trials, including issues of excess fluid retention in participants, which could pose greater safety risks than disclosed.
- Decreased Commercial Viability: As a result of the safety concerns, DCCR's commercial viability is significantly lower than previously indicated, with undisclosed risks potentially leading to higher patient discontinuation rates, prescriber reluctance, adverse regulatory actions, and reputational and legal fallout for the company.
- Shareholder Action Deadline: Shareholders must register by May 5, 2026, to participate in the class action, and upon registration, they will receive updates on the case's progress, ensuring transparency throughout the lifecycle of the lawsuit.
See More
Soleno Therapeutics Shareholder Files Class Action Lawsuit
- Class Action Initiated: Bernstein Liebhard LLP announced that a shareholder has filed a class action lawsuit on behalf of investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) stock between March 26, 2025, and August 4, 2025, alleging misrepresentations regarding the company's Phase 3 clinical trial for DCCR, which may have led to investor losses.
- Lawsuit Details Revealed: The lawsuit requires interested parties to file as lead plaintiff by May 5, 2026, indicating that while the lead plaintiff will represent the class, absent members can still share in any recovery, highlighting the complexities of legal proceedings and the protection of investor rights.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, underscoring its expertise and influence in securities litigation.
- Investor Rights Protection: The initiation of this lawsuit not only provides a legal recourse for affected investors but also emphasizes the need for transparency in corporate communications, potentially prompting the company to enhance compliance and disclosure practices in the future.
See More
Reminder of Class Action Lawsuit Against Soleno Therapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26 and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, or risk losing their chance for compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, including risks of fluid retention in participants, leading to investor losses when the true information was revealed, highlighting major risks in the drug's commercialization.
- Law Firm Credentials: Rosen Law Firm is recognized for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieving the largest securities class action settlement against a Chinese company in 2017, underscoring its leadership in the field.
- Investor Guidance: The firm advises investors to select qualified counsel with proven success, steering clear of firms that merely act as intermediaries, to ensure they receive the best legal support and potential compensation in the class action.
See More
US Stocks Close Higher Amid Hopes for Iran Ceasefire
- Market Recovery: The S&P 500 rose by 0.44% and the Nasdaq 100 increased by 0.61%, both reaching 1.5-week highs, reflecting investor optimism regarding a potential ceasefire in Iran, which could enhance market confidence.
- Economic Data Impact: The US March ISM services index fell to 54.0, below the expected 54.9, indicating a slowdown in service sector growth, which may exert negative pressure on the stock market, prompting investors to monitor future economic trends.
- Strong Labor Market: March nonfarm payrolls surged by 178,000, significantly exceeding expectations of 65,000, while the unemployment rate unexpectedly dropped to 4.3%, indicating a robust US labor market that may provide support for the stock market.
- Oil Price Volatility: Crude oil prices rose by 1% amid escalating tensions in Iran following Trump's military threats, intensifying concerns over energy supply disruptions, which could impact the performance of related stocks.
See More
Soleno Therapeutics Surges 32.39% Following Acquisition Offer from Neurocrine Biosciences
- Acquisition Impact: Soleno Therapeutics' stock surged 32.39% to $52.26 following Neurocrine Biosciences' $53-per-share all-cash acquisition offer, reflecting strong market optimism regarding the deal.
- Volume Surge: Trading volume for Soleno reached 58 million shares, a staggering 2,148% increase over the three-month average of 2.6 million shares, indicating heightened investor interest and reaction to the acquisition news.
- Market Potential: Soleno's VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome patients, has generated sales of $33 million, $66 million, and $92 million over the last three quarters since its launch in March 2025, demonstrating robust market demand.
- Strategic Long-term Value: Neurocrine's $2.9 billion acquisition of Soleno enhances its commercial drug portfolio, with VYKAT XR's intellectual property expected to last into the 2040s, providing significant long-term growth potential, especially given Neurocrine's $2.5 billion cash reserves.
See More
Soleno Therapeutics Stock Soars on Acquisition News from Neurocrine Biosciences
- Acquisition Impact: Neurocrine Biosciences' all-cash offer of $53 per share for Soleno Therapeutics led to a 32.31% surge in its stock price, closing at $52.26, indicating strong market optimism regarding the deal.
- Surge in Trading Volume: Soleno's trading volume reached 58 million shares, a staggering 2,148% increase over its three-month average of 2.6 million shares, reflecting heightened investor interest and market activity surrounding the acquisition.
- Drug Sales Performance: Soleno's flagship drug, VYKAT XR, is the only FDA-approved treatment for patients with Prader-Willi Syndrome, achieving sales of $33 million, $66 million, and $92 million over the last three quarters, showcasing its market potential.
- Long-term Strategic Value: Neurocrine's $2.9 billion acquisition proposal appears manageable given its $2.5 billion cash reserves, while VYKAT XR's intellectual property extending into the 2040s provides significant long-term growth prospects for Neurocrine.
See More
Soleno Therapeutics Shareholder Notice Issued
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Soleno Therapeutics, Inc., encouraging those who purchased SLNO shares between March 26, 2025, and November 4, 2025, to contact the firm regarding potential lead plaintiff status for recovery participation.
- Safety Concerns Allegations: The complaint alleges that Soleno systematically downplayed and concealed significant safety concerns related to its DCCR product during Phase 3 clinical trials, including issues of excess fluid retention in participants, which could pose greater safety risks than disclosed.
- Decreased Commercial Viability: As a result of the safety concerns, DCCR's commercial viability is significantly lower than previously indicated, with undisclosed risks potentially leading to higher patient discontinuation rates, prescriber reluctance, adverse regulatory actions, and reputational and legal fallout for the company.
- Shareholder Action Deadline: Shareholders must register by May 5, 2026, to participate in the class action, and upon registration, they will receive updates on the case's progress, ensuring transparency throughout the lifecycle of the lawsuit.
See More
Soleno Therapeutics Shareholder Files Class Action Lawsuit
- Class Action Initiated: Bernstein Liebhard LLP announced that a shareholder has filed a class action lawsuit on behalf of investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) stock between March 26, 2025, and August 4, 2025, alleging misrepresentations regarding the company's Phase 3 clinical trial for DCCR, which may have led to investor losses.
- Lawsuit Details Revealed: The lawsuit requires interested parties to file as lead plaintiff by May 5, 2026, indicating that while the lead plaintiff will represent the class, absent members can still share in any recovery, highlighting the complexities of legal proceedings and the protection of investor rights.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, underscoring its expertise and influence in securities litigation.
- Investor Rights Protection: The initiation of this lawsuit not only provides a legal recourse for affected investors but also emphasizes the need for transparency in corporate communications, potentially prompting the company to enhance compliance and disclosure practices in the future.
See More
Reminder of Class Action Lawsuit Against Soleno Therapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26 and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, or risk losing their chance for compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, including risks of fluid retention in participants, leading to investor losses when the true information was revealed, highlighting major risks in the drug's commercialization.
- Law Firm Credentials: Rosen Law Firm is recognized for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieving the largest securities class action settlement against a Chinese company in 2017, underscoring its leadership in the field.
- Investor Guidance: The firm advises investors to select qualified counsel with proven success, steering clear of firms that merely act as intermediaries, to ensure they receive the best legal support and potential compensation in the class action.
See More
US Stocks Close Higher Amid Hopes for Iran Ceasefire
- Market Recovery: The S&P 500 rose by 0.44% and the Nasdaq 100 increased by 0.61%, both reaching 1.5-week highs, reflecting investor optimism regarding a potential ceasefire in Iran, which could enhance market confidence.
- Economic Data Impact: The US March ISM services index fell to 54.0, below the expected 54.9, indicating a slowdown in service sector growth, which may exert negative pressure on the stock market, prompting investors to monitor future economic trends.
- Strong Labor Market: March nonfarm payrolls surged by 178,000, significantly exceeding expectations of 65,000, while the unemployment rate unexpectedly dropped to 4.3%, indicating a robust US labor market that may provide support for the stock market.
- Oil Price Volatility: Crude oil prices rose by 1% amid escalating tensions in Iran following Trump's military threats, intensifying concerns over energy supply disruptions, which could impact the performance of related stocks.
See More
Soleno Therapeutics Surges 32.39% Following Acquisition Offer from Neurocrine Biosciences
- Acquisition Impact: Soleno Therapeutics' stock surged 32.39% to $52.26 following Neurocrine Biosciences' $53-per-share all-cash acquisition offer, reflecting strong market optimism regarding the deal.
- Volume Surge: Trading volume for Soleno reached 58 million shares, a staggering 2,148% increase over the three-month average of 2.6 million shares, indicating heightened investor interest and reaction to the acquisition news.
- Market Potential: Soleno's VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome patients, has generated sales of $33 million, $66 million, and $92 million over the last three quarters since its launch in March 2025, demonstrating robust market demand.
- Strategic Long-term Value: Neurocrine's $2.9 billion acquisition of Soleno enhances its commercial drug portfolio, with VYKAT XR's intellectual property expected to last into the 2040s, providing significant long-term growth potential, especially given Neurocrine's $2.5 billion cash reserves.
See More
Soleno Therapeutics Stock Soars on Acquisition News from Neurocrine Biosciences
- Acquisition Impact: Neurocrine Biosciences' all-cash offer of $53 per share for Soleno Therapeutics led to a 32.31% surge in its stock price, closing at $52.26, indicating strong market optimism regarding the deal.
- Surge in Trading Volume: Soleno's trading volume reached 58 million shares, a staggering 2,148% increase over its three-month average of 2.6 million shares, reflecting heightened investor interest and market activity surrounding the acquisition.
- Drug Sales Performance: Soleno's flagship drug, VYKAT XR, is the only FDA-approved treatment for patients with Prader-Willi Syndrome, achieving sales of $33 million, $66 million, and $92 million over the last three quarters, showcasing its market potential.
- Long-term Strategic Value: Neurocrine's $2.9 billion acquisition proposal appears manageable given its $2.5 billion cash reserves, while VYKAT XR's intellectual property extending into the 2040s provides significant long-term growth prospects for Neurocrine.
See More
